Peter J Snyder1, Shalender Bhasin, Glenn R Cunningham, Alvin M Matsumoto, Alisa J Stephens-Shields, Jane A Cauley, Thomas M Gill, Elizabeth Barrett-Connor, Ronald S Swerdloff, Christina Wang, Kristine E Ensrud, Cora E Lewis, John T Farrar, David Cella, Raymond C Rosen, Marco Pahor, Jill P Crandall, Mark E Molitch, Denise Cifelli, Darlene Dougar, Laura Fluharty, Susan M Resnick, Thomas W Storer, Stephen Anton, Shehzad Basaria, Susan J Diem, Xiaoling Hou, Emile R Mohler, J Kellogg Parsons, Nanette K Wenger, Bret Zeldow, J Richard Landis, Susan S Ellenberg. 1. From the Division of Endocrinology, Diabetes, and Metabolism (P.J.S.), the Department of Biostatistics and Epidemiology (A.J.S.-S., J.T.F., X.H., B.Z., J.R.L., S.S.E.), the Center for Clinical Epidemiology and Biostatistics (D. Cifelli, D.D., L.F.), and the Division of Cardiovascular Disease, Section of Vascular Medicine, Department of Medicine (E.R.M.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston (S. Bhasin, T.W.S., S. Basaria), and New England Research Institutes, Watertown (R.C.R.) - both in Massachusetts; the Departments of Medicine and Molecular and Cellular Biology, Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine and Baylor St. Luke's Medical Center, Houston (G.R.C.); Geriatric Research, Education, and Clinical Center, Department of Veterans Affairs (VA) Puget Sound Health Care System, and the Division of Gerontology and Geriatric Medicine, Department of Internal Medicine, University of Washington School of Medicine - both in Seattle (A.M.M.); the Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh (J.A.C.); the Division of Geriatric Medicine, Yale School of Medicine, New Haven, CT (T.M.G.); the Department of Internal Medicine and Division of Epidemiology, Department of Family Medicine and Public Health, University of California, San Diego, School of Medicine, La Jolla (E.B.-C.), the Division of Endocrinology, Harbor-UCLA Medical Center (R.S.S., C.W.), and Los Angeles Biomedical Research Institute (R.S.S., C.W.), Torrance, and the Department of Urology, Moores Comprehensive Cancer Center, University of California, San Diego (J.K.P.) - all in California; the Department of Medicine, Division of Epidemiology and Community Health, University of Minnesota (K.E.E., S.J.D.), and Minneapolis VA Health Care System (K.E.E.) - both in Minneapolis; the D
Abstract
BACKGROUND:Serum testosterone concentrations decrease as men age, but benefits of raising testosterone levels in older men have not been established. METHODS: We assigned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms suggesting hypoandrogenism to receive eithertestosterone gel or placebo gelfor 1 year. Each man participated in one or more of three trials--the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial. The primary outcome of each of the individual trials was also evaluated in all participants. RESULTS:Testosterone treatment increased serum testosterone levels to the mid-normal range for men 19 to 40 years of age. The increase in testosterone levels was associated with significantly increased sexual activity, as assessed by the Psychosexual Daily Questionnaire (P<0.001), as well as significantly increased sexual desire and erectile function. The percentage of men who had an increase of at least 50 m in the 6-minute walking distance did not differ significantly between the two study groups in the Physical Function Trial but did differ significantly when men in all three trials were included (20.5% of men who received testosterone vs. 12.6% of men who received placebo, P=0.003). Testosterone had no significant benefit with respect to vitality, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue scale, but men who received testosterone reported slightly better mood and lower severity of depressive symptoms than those who received placebo. The rates of adverse events were similar in the two groups. CONCLUSIONS: In symptomatic men 65 years of age or older, raising testosterone concentrations for 1 year from moderately low to the mid-normal range for men 19 to 40 years of age had a moderate benefit with respect to sexual function and some benefit with respect to mood and depressive symptoms but no benefit with respect to vitality or walking distance. The number of participants was too few to draw conclusions about the risks of testosterone treatment. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00799617.).
RCT Entities:
BACKGROUND: Serum testosterone concentrations decrease as men age, but benefits of raising testosterone levels in older men have not been established. METHODS: We assigned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms suggesting hypoandrogenism to receive either testosterone gel or placebo gel for 1 year. Each man participated in one or more of three trials--the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial. The primary outcome of each of the individual trials was also evaluated in all participants. RESULTS:Testosterone treatment increased serum testosterone levels to the mid-normal range for men 19 to 40 years of age. The increase in testosterone levels was associated with significantly increased sexual activity, as assessed by the Psychosexual Daily Questionnaire (P<0.001), as well as significantly increased sexual desire and erectile function. The percentage of men who had an increase of at least 50 m in the 6-minute walking distance did not differ significantly between the two study groups in the Physical Function Trial but did differ significantly when men in all three trials were included (20.5% of men who received testosterone vs. 12.6% of men who received placebo, P=0.003). Testosterone had no significant benefit with respect to vitality, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue scale, but men who received testosterone reported slightly better mood and lower severity of depressive symptoms than those who received placebo. The rates of adverse events were similar in the two groups. CONCLUSIONS: In symptomatic men 65 years of age or older, raising testosterone concentrations for 1 year from moderately low to the mid-normal range for men 19 to 40 years of age had a moderate benefit with respect to sexual function and some benefit with respect to mood and depressive symptoms but no benefit with respect to vitality or walking distance. The number of participants was too few to draw conclusions about the risks of testosterone treatment. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00799617.).
Authors: Giovanni Corona; Elisa Maseroli; Giulia Rastrelli; Andrea M Isidori; Alessandra Sforza; Edoardo Mannucci; Mario Maggi Journal: Expert Opin Drug Saf Date: 2014-08-19 Impact factor: 4.250
Authors: Thomas G Travison; Shehzad Basaria; Thomas W Storer; Alan M Jette; Renee Miciek; Wildon R Farwell; Karen Choong; Kishore Lakshman; Norman A Mazer; Andrea D Coviello; Philip E Knapp; Jagadish Ulloor; Anqi Zhang; Brad Brooks; Ahn-Hoa Nguyen; Richard Eder; Nathan LeBrasseur; Ayan Elmi; Erica Appleman; Leife Hede-Brierley; Geeta Bhasin; Ashmeet Bhatia; Antonio Lazzari; Samuel Davis; Pengsheng Ni; Lauren Collins; Shalender Bhasin Journal: J Gerontol A Biol Sci Med Sci Date: 2011-06-22 Impact factor: 6.053
Authors: Stephanie T Page; John K Amory; F Dubois Bowman; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; J Lisa Tenover Journal: J Clin Endocrinol Metab Date: 2004-11-30 Impact factor: 5.958
Authors: Frederick C W Wu; Abdelouahid Tajar; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe Casanueva; Gianni Forti; Aleksander Giwercman; Ilpo T Huhtaniemi; Krzysztof Kula; Margus Punab; Steven Boonen; Dirk Vanderschueren Journal: J Clin Endocrinol Metab Date: 2008-02-12 Impact factor: 5.958
Authors: Glenn R Cunningham; Alisa J Stephens-Shields; Raymond C Rosen; Christina Wang; Shalender Bhasin; Alvin M Matsumoto; J Kellogg Parsons; Thomas M Gill; Mark E Molitch; John T Farrar; David Cella; Elizabeth Barrett-Connor; Jane A Cauley; Denise Cifelli; Jill P Crandall; Kristine E Ensrud; Laura Gallagher; Bret Zeldow; Cora E Lewis; Marco Pahor; Ronald S Swerdloff; Xiaoling Hou; Stephen Anton; Shehzad Basaria; Susan J Diem; Vafa Tabatabaie; Susan S Ellenberg; Peter J Snyder Journal: J Clin Endocrinol Metab Date: 2016-06-29 Impact factor: 5.958
Authors: Thomas W Storer; Shalender Bhasin; Thomas G Travison; Karol Pencina; Renee Miciek; Jennifer McKinnon; Shehzad Basaria Journal: J Clin Endocrinol Metab Date: 2016-04-06 Impact factor: 5.958
Authors: Annewieke W van den Beld; Jean-Marc Kaufman; M Carola Zillikens; Steven W J Lamberts; Josephine M Egan; Aart J van der Lely Journal: Lancet Diabetes Endocrinol Date: 2018-07-17 Impact factor: 32.069
Authors: Richard V Clark; Ann C Walker; Susan Andrews; Philip Turnbull; Jeffrey A Wald; Mindy H Magee Journal: Br J Clin Pharmacol Date: 2017-06-10 Impact factor: 4.335
Authors: Erik L Knight; Colton B Christian; Pablo J Morales; William T Harbaugh; Ulrich Mayr; Pranjal H Mehta Journal: Psychoneuroendocrinology Date: 2017-08-18 Impact factor: 4.905
Authors: Shehzad Basaria; Ravi Jasuja; Grace Huang; Whitney Wharton; Hong Pan; Karol Pencina; Zhuoying Li; Thomas G Travison; Jag Bhawan; Renaud Gonthier; Fernand Labrie; Alain Y Dury; Carlo Serra; Allen Papazian; Michael O'Leary; Sami Amr; Thomas W Storer; Emily Stern; Shalender Bhasin Journal: J Clin Endocrinol Metab Date: 2016-09-23 Impact factor: 5.958